Maxim Group reaffirmed their buy rating on shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) in a research report sent to investors on Thursday, November 2nd. The firm currently has a $23.00 target price on the biopharmaceutical company’s stock.
A number of other equities research analysts also recently issued reports on SCMP. TheStreet downgraded Sucampo Pharmaceuticals from a c+ rating to a d rating in a research report on Wednesday, August 2nd. Roth Capital set a $30.00 price target on Sucampo Pharmaceuticals and gave the company a buy rating in a research report on Thursday, August 3rd. BidaskClub downgraded Sucampo Pharmaceuticals from a buy rating to a hold rating in a research report on Saturday, August 5th. Leerink Swann began coverage on Sucampo Pharmaceuticals in a research report on Monday, August 21st. They set an outperform rating and a $15.00 price target on the stock. Finally, Mizuho downgraded Sucampo Pharmaceuticals from a buy rating to a neutral rating and lowered their price target for the company from $14.00 to $12.00 in a research report on Tuesday, October 3rd. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $16.22.
Sucampo Pharmaceuticals (NASDAQ SCMP) traded down $0.40 during trading hours on Thursday, hitting $10.30. The company’s stock had a trading volume of 459,400 shares, compared to its average volume of 653,364. The stock has a market capitalization of $481.53, a P/E ratio of 7.33, a P/E/G ratio of 3.21 and a beta of 1.38. Sucampo Pharmaceuticals has a 12-month low of $9.30 and a 12-month high of $17.55. The company has a current ratio of 5.11, a quick ratio of 4.46 and a debt-to-equity ratio of 7.37.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The firm had revenue of $61.27 million for the quarter, compared to the consensus estimate of $58.05 million. During the same quarter in the prior year, the business posted $0.30 earnings per share. The business’s quarterly revenue was up 5.9% on a year-over-year basis. equities analysts forecast that Sucampo Pharmaceuticals will post 1.11 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Maxim Group Reiterates “Buy” Rating for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)” was originally reported by Week Herald and is the property of of Week Herald. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://weekherald.com/2017/11/15/maxim-group-reaffirms-buy-rating-for-sucampo-pharmaceuticals-inc-scmp.html.
In other news, insider Jason Patrick Meyenburg acquired 4,000 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were acquired at an average cost of $12.13 per share, with a total value of $48,520.00. Following the transaction, the insider now owns 30,228 shares in the company, valued at approximately $366,665.64. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of Sucampo Pharmaceuticals stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $12.00, for a total value of $12,000,000.00. The disclosure for this sale can be found here. 4.13% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp lifted its holdings in shares of Sucampo Pharmaceuticals by 107.3% during the first quarter. Bank of New York Mellon Corp now owns 367,691 shares of the biopharmaceutical company’s stock valued at $4,044,000 after purchasing an additional 190,292 shares during the last quarter. Karp Capital Management Corp purchased a new position in shares of Sucampo Pharmaceuticals during the first quarter valued at approximately $119,000. Ameriprise Financial Inc. purchased a new position in shares of Sucampo Pharmaceuticals during the first quarter valued at approximately $1,431,000. Arizona State Retirement System purchased a new position in shares of Sucampo Pharmaceuticals during the first quarter valued at approximately $142,000. Finally, American International Group Inc. lifted its holdings in shares of Sucampo Pharmaceuticals by 7.1% during the first quarter. American International Group Inc. now owns 14,420 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 951 shares during the last quarter. 56.79% of the stock is currently owned by institutional investors and hedge funds.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.